Modified Citrus Pectin Research

2018 Clinical Study (Interim Results): Modified Citrus Pectin Halts Biochemically Relapsed Prostate Cancer

2018 Preclinical Study: Modified Citrus Pectin Inhibits Colon Cancer Migration via Galectin-3 Inhibition

2018 Practice Survey: Modified Citrus Pectin at Top of List for Naturopathic Treatment of Thoracic Cancer

2018 Preclinical Study: Modified Citrus Pectin Enhances Radiotherapy Against Prostate Cancer

2018 Preclinical Study: Modified Citrus Pectin Increases Antioxidant Activity and Reduces Oxidative Stress in Hypertension Model, through Inhibition of Galectin-3

2018 Preclinical Study: Modified Citrus Pectin Inhibits Bladder Tumor Growth through Downregulation of Galectin-3

2018 Preclinical Study: Inhibition of Galectin-3 with Modified Citrus Pectin Mitigates Diet-Induced Cardiac Lipotoxicity and Reduces Mitochondrial Damage

2018 Preclinical Study: Inhibition of Galectin-3 with Modified Citrus Pectin Reduces Inflammatory Mediators and Decreases Kidney Damage in Spontaneous Hypertension Model

2017 Preclinical Study: Modified Citrus Pectin Protects Vascular Tissue against Abdominal Aortic Aneurism by Decreasing Galectin-3 and Inflammatory Cytokine Expression

2017 Preclinical Study: Modified Citrus Pectin Combined with Alginate and Live Probiotic, Lactobacillus acidophilus Offered Benefit to Improve the Intestinal Lactobacilli Microbiota in Healthy Host

2017 Observational Study: Modified Citrus Pectin Listed Among Researched Nutrients with Anti-Carcinogenic Properties to Reduce CTC Count

2017 Preclinical Study: Modified Citrus Pectin Protects Against Shiga Toxin Adhesion and Cytotoxicity, via Prebiotic Actions

2017 Preclinical Study: Modified Citrus Pectin Reduces Size of Atherosclerotic Lesions, via Inhibition of Galectin-3

2017 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 to Prevent Cardiac Remodeling, Fibrosis and Inflammation Associated with Early Aortic Stenosis

2017 Preclinical Study: Modified Citrus Pectin and Pure Honokiol Offer Synergistic Antioxidant and Anti-inflammatory Effects, Reduce Tumor Necrosis-α (TNF-α), Nuclear factor-kappa B, Cyclooxygenase-II, and Lipid Peroxidation

2017 Preclinical Study: Modified Citrus Pectin Gives Additive Antibacterial Effect in Combination with Cefotaxime Against Staphylococcus aureusInfection

2017 Preclinical Study: Galectin-3 inhibition with Modified Citrus Pectin Blocks Inflammation, Fibrosis and Calcification in Aortic Valves

2016 Preclinical Study: Modified Citrus Pectin Reduces Renal Fibrosis, Inflammation and Damage, Through Inhibition of Galectin-3

2016 Preclinical Study: Modified Citrus Pectin Blocks Inflammation and Fibrosis and Prevents Calcification in Aortic Stenosis, via Inhibition of Galectin-3

2016 Preclinical Study: Modified Citrus Pectin Prevents Adipose (Fat)Tissue Remodeling in Obesity, via Inhibition of Galectin-3

2016 Preclinical Study: Modified Citrus Pectin Stops Progression of Liver Fibrosis Through Antioxidant Effect, Galectin-3 Inhibitionand Induction of Apoptosis

2016 Preclinical Study: Modified Citrus Pectin Inhibits Growth and Metastasis of Gastrointestinal Cancer Cells

2016 Preclinical Study: Modified Citrus Pectin Prevents Left Ventricle Dysfunction and Cardiac Fibrosis, through Inhibition of Galectin-3

2016 Preclinical Study: Modified Citrus pectin Suppresses Neuropathic Pain and Decreases Proinflammatory Mediators Following Peripheral Nerve Injury, via Inhibition of Galectin-3

2015 Preclinical Study: Modified Citrus Pectin Prevents Obesity-Related Cardiovascular Remodeling, through Inhibition of Galectin-3

2015 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 to Inhibit Cardiac Inflammation and Fibrosis in Experimental Hypertension

2015 Preclinical Study: Modified Citrus Pectin and Alginate Probiotic Combination offer Chemopreventive Effect against Colon Cancer Cells

2015 Preclinical Study: Modified Citrus Pectin Prevents Cardiac and Kidney Fibrosis, via Inhibition of Galectin-3

2013 Preclinical Study: Modified Citrus Pectin Reverses Vascular Hypertrophy and Fibrosis, via Inhibition of Galectin-3

2013 Preclinical Study: Modified Citrus Pectin Traverses Small Intestinal Epithelium Demonstrating increased Bioavailability

2013 Preclinical Study: Modified Citrus Pectin Demonstrates Synergistic Effect with Polybotanical Compounds for Breast and Prostate Cancer

2012 Preclinical Study: Synergistic Effects of Modified Citrus Pectin and Doxorubicin against Prostate Cancer Cells

2011 Preclinical Study: Modified Citrus Pectin Reduces Kidney Disease Severity by Reducing Galectin-3 Expression

2011 Preclinical Study: Modified Citrus Pectin Activates Powerful Immune Response

2011 Preclinical Study: Activation and Induction of Natural Killer Cell Activity Against Leukemia Cells with Modified Citrus Pectin

2010 Preclinical Study: Modified Citrus Pectin Inhibits Prostate Cancer

2010 Review: Modified Citrus Pectin Anti-Metastatic Properties

2009 Preclinical Study: Modified Citrus Pectin Binds to Galectin-3

2008 Clinical Study: The Role of Modified Citrus Pectin as an Effective Chelator of Lead in Children Hospitalized with Toxic Lead Levels

2007 Clinical Study: The Role of Modified Citrus Pectin/Alginates in Heavy Metal Chelation and Detoxification

2007 Clinical Study: Modified Citrus Pectin Clinical Benefit in Patients with Advanced Solid Tumors

2006 Clinical Study: The Effect of Modified Citrus Pectin on the Urinary Excretion of Toxic Elements

2003 Clinical Study: Modified Citrus Pectin (MCP) Increases the Prostate-Specific Antigen Doubling Time in Men with Prostate Cancer: A Phase II Pilot Study

To Read More, visit: PubMed